$350 | Single User
$700 | Site License
$1050 | Enterprise License

Pharmaceuticals in South Korea [Report Updated: 06-06-2018]

Published by Marketline: 06 Jun 2018 | 218179 | In Stock

Introduction

Pharmaceuticals in South Korea

Summary

Pharmaceuticals in South Korea industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2013-17, and forecast to 2022). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Synopsis

Essential resource for top-line data and analysis covering the South Korea pharmaceuticals market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Key highlights

- The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare.

- The South Korean pharmaceuticals market had total revenues of .1bn in 2017, representing a compound annual growth rate (CAGR) of 2.3% between 2013 and 2017.

- South Korea has been classed as a developed pharmaceuticals market since 2010. As such it suffers classic problems that other developed markets are experiencing which will lead to increased spending.

- Despite an aging population and being one of the most sophisticated healthcare systems in the world, the value of the pharmaceutical market is only forecast to accelerate slightly throughout the forecast period.

Scope

- Save time carrying out entry-level research by identifying the size, growth, and leading players in the pharmaceuticals market in South Korea

- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the pharmaceuticals market in South Korea

- Leading company profiles reveal details of key pharmaceuticals market players’ global operations and financial performance

- Add weight to presentations and pitches by understanding the future growth prospects of the South Korea pharmaceuticals market with five year forecasts

Reasons to buy

- What was the size of the South Korea pharmaceuticals market by value in 2017?

- What will be the size of the South Korea pharmaceuticals market in 2022?

- What factors are affecting the strength of competition in the South Korea pharmaceuticals market?

- How has the market performed over the last five years?

- Who are the top competitiors in South Korea's pharmaceuticals market?

Table of Contents
for Pharmaceuticals in South Korea [Report Updated: 06-06-2018]

  • Table of Contents

    Executive Summary 2

    Market value 2

    Market value forecast 2

    Geography segmentation 2

    Market share 2

    Market rivalry 2

    Market Overview 7

    Market definition 7

    Market analysis 7

    Market Data 9

    Market value 9

    Market Segmentation 10

    Geography segmentation 10

    Market share 11

    Market Outlook 12

    Market value forecast 12

    Five Forces Analysis 13

    Summary 13

    Buyer power 14

    Supplier power 16

    New entrants 17

    Threat of substitutes 19

    Degree of rivalry 20

    Leading Companies 22

    CKD Bio Corporation 22

    Daewoong Pharmaceutical Co Ltd 25

    Hanmi Science Co., Ltd. 29

    Pfizer Inc. 32

    Macroeconomic Indicators 36

    Country data 36

    Methodology 38

    Industry associations 39

    Related MarketLine research 39

    Appendix 40

    About MarketLine 40

List Of Tables
in Pharmaceuticals in South Korea [Report Updated: 06-06-2018]

List of Tables

Table 1: South Korea pharmaceuticals market value: $ billion, 2013-17

Table 2: South Korea pharmaceuticals market geography segmentation: $ billion, 2017

Table 3: South Korea pharmaceuticals market share: % share, by value, 2017

Table 4: South Korea pharmaceuticals market value forecast: $ billion, 2017-22

Table 5: CKD Bio Corporation: key facts

Table 6: CKD Bio Corporation: key financials ($)

Table 7: CKD Bio Corporation: key financials (KRW)

Table 8: CKD Bio Corporation: key financial ratios

Table 9: Daewoong Pharmaceutical Co Ltd: key facts

Table 10: Daewoong Pharmaceutical Co Ltd: key financials ($)

Table 11: Daewoong Pharmaceutical Co Ltd: key financials (KRW)

Table 12: Daewoong Pharmaceutical Co Ltd: key financial ratios

Table 13: Hanmi Science Co., Ltd.: key facts

Table 14: Hanmi Science Co., Ltd.: key financials ($)

Table 15: Hanmi Science Co., Ltd.: key financials (KRW)

Table 16: Hanmi Science Co., Ltd.: key financial ratios

Table 17: Pfizer Inc.: key facts

Table 18: Pfizer Inc.: key financials ($)

Table 19: Pfizer Inc.: key financial ratios

Table 20: South Korea size of population (million), 2013-17

Table 21: South Korea gdp (constant 2005 prices, $ billion), 2013-17

Table 22: South Korea gdp (current prices, $ billion), 2013-17

Table 23: South Korea inflation, 2013-17

Table 24: South Korea consumer price index (absolute), 2013-17

Table 25: South Korea exchange rate, 2013-17

List Of Figures, Charts and Diagrams
in Pharmaceuticals in South Korea [Report Updated: 06-06-2018]

List of Figures

Figure 1: South Korea pharmaceuticals market value: $ billion, 2013-17

Figure 2: South Korea pharmaceuticals market geography segmentation: % share, by value, 2017

Figure 3: South Korea pharmaceuticals market share: % share, by value, 2017

Figure 4: South Korea pharmaceuticals market value forecast: $ billion, 2017-22

Figure 5: Forces driving competition in the pharmaceuticals market in South Korea, 2017

Figure 6: Drivers of buyer power in the pharmaceuticals market in South Korea, 2017

Figure 7: Drivers of supplier power in the pharmaceuticals market in South Korea, 2017

Figure 8: Factors influencing the likelihood of new entrants in the pharmaceuticals market in South Korea, 2017

Figure 9: Factors influencing the threat of substitutes in the pharmaceuticals market in South Korea, 2017

Figure 10: Drivers of degree of rivalry in the pharmaceuticals market in South Korea, 2017

Figure 11: CKD Bio Corporation: revenues & profitability

Figure 12: CKD Bio Corporation: assets & liabilities

Figure 13: Daewoong Pharmaceutical Co Ltd: revenues & profitability

Figure 14: Daewoong Pharmaceutical Co Ltd: assets & liabilities

Figure 15: Hanmi Science Co., Ltd.: revenues & profitability

Figure 16: Hanmi Science Co., Ltd.: assets & liabilities

Figure 17: Pfizer Inc.: revenues & profitability

Figure 18: Pfizer Inc.: assets & liabilities

Additional Details

Publisher

Marketline

Publisher Information

Reference

218179 |

Number of Pages

41

Report Format

PDF

Marketline Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Alexion Pharmaceuticals Partnering Deals and Alliances 2010 to 2016
The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering...
01 Oct 2016 by Current Partnering USD $1,495 More Info
Alnylam Pharmaceuticals Partnering Deals and Alliances 2010 to 2016
The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering...
01 Oct 2016 by Current Partnering USD $1,495 More Info
AMAG Pharmaceuticals Partnering Deals and Alliances 2010 to 2016
The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering...
01 Oct 2016 by Current Partnering USD $1,495 More Info
Amylin Pharmaceuticals Partnering Deals and Alliances 2010 to 2016
The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering...
01 Oct 2016 by Current Partnering USD $1,495 More Info
BioCryst Pharmaceuticals Partnering Deals and Alliances 2010 to 2016
The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering...
01 Oct 2016 by Current Partnering USD $1,495 More Info
Biomarin Pharmaceuticals Partnering Deals and Alliances 2010 to 2016
The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering...
01 Oct 2016 by Current Partnering USD $1,495 More Info
Enzon Pharmaceuticals Partnering Deals and Alliances 2010 to 2016
The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering...
01 Oct 2016 by Current Partnering USD $1,495 More Info
Essilor Pharmaceuticals Partnering Deals and Alliances 2010 to 2016
The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering...
01 Oct 2016 by Current Partnering USD $1,495 More Info
Isis Pharmaceuticals Partnering Deals and Alliances 2010 to 2016
The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering...
01 Oct 2016 by Current Partnering USD $1,495 More Info
NPS Pharmaceuticals Partnering Deals and Alliances 2010 to 2016
The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering...
01 Oct 2016 by Current Partnering USD $1,495 More Info

This report is published by Marketline

Download Free Report Summary PDF

Pharmaceuticals in South Korea [Report Updated: 06-06-2018] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • Allied Market Research
  • CBR Pharma
  • Current Partnering
  • Firstword
  • Global Data
  • Global Markets Direct
  • ICD Research
  • Infinti Research Technavio
  • Marketline
  • Markets and Markets
  • Micro Markets Monitor
  • MP Advisors
  • Venture Planning Group
  • GMR Data